Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Type 2 Diabetes
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 41
States / cities: Sheffield, Alabama • Surprise, Arizona • Tucson, Arizona + 36 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, Placebo, RO5190591 (Danoprevir); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more

Conditions: Opioid Use Disorder
Interventions: Placebo, MCAM; Other · Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gout
Interventions: RDEA594, Placebo, Allopurinol; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more

Conditions: Healthy Volunteer
Interventions: BIIB144, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more

Conditions: Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
Interventions: Placebo Oral Capsule, NYX-458; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more

Conditions: Diabetes
Interventions: Study Arm A, Study Arm B, Study Arm C, Study Arm D; Dietary Supplement
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pharmacokinetics, Healthy Volunteers
Interventions: BTA-C585 oral capsules, BTA-C585 matching placebo; Drug
Lead sponsor: Biota Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain, Postoperative Depression
Interventions: Ketamine, Placebo Comparator; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TRL345, a human monoclonal antibody; Drug
Lead sponsor: Trellis Bioscience LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Overweight, Healthy Subjects
Interventions: SAR441255, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Glabellar Frown Lines (GL)
Interventions: EB-001 injection, Placebo injection; Drug
Lead sponsor: Bonti, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Fremont, California • Newport Beach, California

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: REGN1193, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia • Knoxville, Tennessee

Conditions: Obesity, Obese
Interventions: HM17321, Placebo of HM17321; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Subjects
Interventions: EDG-7500, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions: NNC0365-3769 (Mim8), Placebo (Mim8); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Interventions: Vitamin C, Placebo; Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dengue Disease, Dengue Virus
Interventions: V181 High-Potency Level, V181 Mid-Potency Level, V181 Low-Potency Level, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1,271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: San Diego, California • Miami, Florida • Rochester, New York + 3 more

Search by objective public record fields.

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

Allopurinol Combination Study

A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Vitamins C and Vitamin E and Cardiovascular Risk

Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

A Study of EDG-7500 in Healthy Adults

A Research Study Investigating Mim8 in People With Haemophilia A

Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)